These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38287880)

  • 1. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
    Hooijberg F; Layegh Z; Leeuw M; Boekel L; van den Berg SPH; Ruwaard J; Bastida C; Huitema ADR; Pel S; Elkayam O; de Vries A; Nurmohamed M; Rispens T; Dorlo TPC; Wolbink G
    Ther Drug Monit; 2024 Jun; 46(3):410-414. PubMed ID: 38287880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.
    Bastida C; Huitema ADR; l'Ami MJ; Ruiz-Esquide V; Wolbink GJ; Sanmartí R; Soy D
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1417-1425. PubMed ID: 32514745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
    Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
    Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.
    Alperi-López M; Alonso-Castro S; Morante-Bolado I; Queiro-Silva R; Riestra-Noriega JL; Arboleya L; Ballina-García FJ
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):319-323. PubMed ID: 30318269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
    Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
    Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Lu P; Rowell L; Bao M; Mysler EF
    Ann Rheum Dis; 2014 Jan; 73(1):69-74. PubMed ID: 23904473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.
    Bastida C; Soy D; Ruiz-Esquide V; Sanmartí R; Huitema ADR
    Br J Clin Pharmacol; 2019 Aug; 85(8):1710-1718. PubMed ID: 30958574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
    Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T;
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
    Emery P; Rondon J; Parrino J; Lin Y; Pena-Rossi C; van Hoogstraten H; Graham NMH; Liu N; Paccaly A; Wu R; Spindler A
    Rheumatology (Oxford); 2019 May; 58(5):849-858. PubMed ID: 30590833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity.
    van Herwaarden N; Herfkens-Hol S; van der Maas A; van den Bemt BJ; van Vollenhoven RF; Bijlsma JW; den Broeder AA
    Clin Exp Rheumatol; 2014; 32(3):390-4. PubMed ID: 24773727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.